Healthcare / BiotechnologyNasdaqCM
$9.29
-0.25 (-2.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-97.2M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$87M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-380.0%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-105.6M · FCF $-45.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-105.6M | $-105.6M | $-96.9M | $-117.7M | $-95.6M | $-54.9M | $-20.0M | $-5.2M |
| EBITDA | $-33.2M | $-33.2M | $-95.8M | $-126.0M | $-88.0M | — | — | — |
| EPS | -24.70 | -24.70 | -25.20 | -30.90 | -25.30 | -14.90 | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | — | — | — |
| Current Ratio | 10.38 | 10.38 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-45.7M | $-45.7M | $-97.2M | $-101.1M | $-73.6M | $-44.7M | $-26.4M | — |
| Returns | ||||||||
| ROE | -380.0% | -380.0% | -216.2% | -90.4% | -40.7% | -17.1% | -7.3% | 26.2% |
| Valuation | ||||||||
| P/B | 1.43 | 1.43 | 0.49 | 0.84 | 0.55 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | 2.0% | 2.0% | 18.4% | -22.1% | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+196.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-25.20 → -24.70
Residual
+196.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.